Combining Targeted Demethylation with Noncoding RNA-mediated mRNA Stabilization as a Strategy for Therapeutic Arteriogenesis in the Aged
将靶向去甲基化与非编码 RNA 介导的 mRNA 稳定相结合作为治疗老年人动脉生成的策略
基本信息
- 批准号:10826740
- 负责人:
- 金额:$ 6.79万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-04-01 至 2026-03-31
- 项目状态:未结题
- 来源:
- 关键词:3&apos Untranslated RegionsAcuteAgeAgingAngioplastyAtherosclerosisBindingBinding SitesBiogenesisBlood CellsBlood VesselsBlood flowBypassCholesterolChronicClinicalCpG IslandsDNADNA MethylationDataDiabetes MellitusDiseaseDoseGenesGrantGrowthHalf-LifeHomeostasisImpairmentInfiltrationInflammatoryInjuryIntegrinsInterleukin-1 betaIschemiaLeadLesionLigationMacrophageMechanicsMediatingMedicineMessenger RNAMethylationMicroRNAsModelingMolecularMorbidity - disease rateMusMuscleMyelogenousOperative Surgical ProceduresOutcomePathway interactionsPerceptionPeripheral arterial diseasePersonsPhenotypePlayProtein IsoformsProteinsRecoveryRoleSignal PathwaySignal TransductionSiteSourceTherapeuticTissue PreservationTissuesTranscriptTranscription CoactivatorTransfectionTranslationsUntranslated RNAVEGFA geneVascular DiseasesVascular Endothelial Growth FactorsVascularizationadhesion receptorage effectage relatedagedangiogenesischemokine receptorcytokinedemethylationfallsfemoral arteryhealingimprovedinhibitorlimb ischemiamRNA InstabilitymRNA Stabilitymortalitynew growthnovelolder patientposttranscriptionalpromoterresponse to injurysynergismtherapy developmenttranslational potentialtreatment strategy
项目摘要
ABSTRACT:
Aging and age-related diseases like peripheral artery disease (PAD) lead to considerable morbidity and
mortality. Aging is associated with impaired inflammatory arteriogenesis responses to injury. We defined a
macrophage signaling axis that activates the mRNA stabilizing protein, HuR, to promote VEGF-A expression
required for arteriogenesis. We seek to understand the effects of aging on this pathway. Moderately aged (52-
week-old) mice demonstrated reduced blood flow recovery and decreased arteriogenesis relative to young (12-
week-old) mice in a femoral artery ligation model of ischemia. In aged mice, ischemic muscle tissue and
macrophages revealed reduced VEGF-A expression. Aged macrophages demonstrated increased global DNA
methylation, and though macrophage HuR expression was normal, there was reduced HuR binding to VEGF-A
mRNA with consequent shortened VEGF-A mRNA half-life. Somewhat surprisingly, Dicer1, previously
established as destabilizing for VEGF-A mRNA, was downregulated in aged macrophages. The DNMT
inhibitor, RG108, led to increased Dicer1 and VEGF-A expression and increased HuR binding to VEGF-A
mRNA. miR-29, as a 3p miRNA, appears to be particularly sensitive to changes in Dicer1 expression. Aged
macrophages had decreased expression of miR-29, whose seeding site in the 3′-UTR of VEGF-A is adjacent
to the HuR binding site. Transfection of macrophages with miR-29 mimic increased VEGF-A expression.
Myeloid Dicer1-deleted mice were phenotypically similar to aged mice, having decreased blood flow recovery,
decreased VEGF-A expression, and decreased HuR binding to VEGF-A mRNA with consequent shortened
mRNA half-life. Our hypothesis is that aging acquired methylation of Dicer1 with consequent reductions in
Dicer1 dose-sensitive microRNAs (i.e. miR-29-3p) results in reduced binding of HuR to VEGF-A mRNA and
reductions in both VEGF-A expression and consequent VEGF-A dependent angio/ arteriogenesis. Our aims
seek to 1) define Dicer1 promoter methylation in aged mice to be a major mechanism of impaired VEGF-A-
mediated arteriogenesis with aging; and 2) define the molecular mechanisms whereby the Dicer1 dose-
sensitive microRNA, miR-29-3p, promotes HuR-binding to VEGF-A mRNA with consequent message
stabilization. Our studies will lead to a paradigm shift from Dicer1 as a negative regulator of VEGF-A to that of
a positive regulator. The rescue of macrophage VEGF-A expression by demethylation of Dicer1 or noncoding
RNA (i.e. miR-29) mimics, may have profound implications in the development of treatment strategies that can
promote arteriogenesis and associated tissue preservation in the setting of severe age-related vasculopathies.
摘要:
老龄化和与年龄相关的疾病,如外周动脉疾病(PAD),导致相当大的发病率和
死亡率。衰老与损伤引起的炎性动脉生成反应受损有关。我们定义了一个
巨噬细胞信号轴激活mRNA稳定蛋白HUR促进血管内皮生长因子-A的表达
动脉形成所必需的。我们试图了解衰老对这一途径的影响。中年(52-
周龄小鼠的血流恢复和动脉生成较年轻小鼠减少(12-
周龄)小鼠建立股动脉结扎缺血模型。在老龄小鼠中,缺血肌肉组织和
巨噬细胞显示VEGF-A表达降低。衰老的巨噬细胞表现为全球DNA增加
甲基化,尽管巨噬细胞HUR表达正常,但HUR与VEGF-A的结合减少
信使VEGF-A信使核糖核酸半衰期缩短。有点令人惊讶的是,Dicer1之前
在衰老的巨噬细胞中表达下调,被认为是血管内皮生长因子-A的失稳基因。DNMT
抑制剂RG108导致Dicer1和VEGF-A表达增加,并增加Hur与VEGF-A的结合
MRNA.MIR-29作为一种3p的miRNA,似乎对Dicer1表达的变化特别敏感。老态
巨噬细胞的miR-29表达降低,其种植部位位于VEGF-A的3‘端非编码区附近
到HUR结合部位。将miR-29基因导入巨噬细胞可模拟血管内皮细胞生长因子-A的表达。
髓系Dicer1缺失的小鼠与老龄小鼠的表型相似,血流恢复较慢,
降低血管内皮生长因子-A的表达,减少HUR与血管内皮生长因子-A mRNA的结合,从而缩短
信使核糖核酸半衰期。我们的假设是,衰老获得了Dicer1的甲基化,从而减少了
DICER1剂量敏感的microRNAs(即miR-29-3p)导致HUR与VEGF-A mRNA的结合减少
血管内皮生长因子-A的表达减少以及由此导致的血管/动脉生成依赖。我们的目标
寻求1)确定Dicer1启动子甲基化是老年小鼠血管内皮生长因子-A受损的主要机制。
以及2)确定Dicer1参与的分子机制。
敏感的microRNA,miR-29-3p,促进与VEGF-A mRNA的Hur结合,从而传递信息
稳定状态。我们的研究将导致范式的转变,从Dicer1作为VEGF-A的负调节因子,到Dicer1
一个积极的监管机构。Dicer1去甲基化或非编码对巨噬细胞血管内皮生长因子-A表达的挽救作用
RNA(即miR-29)模拟,可能在开发治疗策略方面具有深远的影响,
在严重的年龄相关性血管病变的背景下,促进动脉生成和相关组织的保存。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Alan Ross Morrison其他文献
Alan Ross Morrison的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Alan Ross Morrison', 18)}}的其他基金
Combining Targeted Demethylation with Noncoding RNA-mediated mRNA Stabilization as a Strategy for Therapeutic Arteriogenesis in the Aged
将靶向去甲基化与非编码 RNA 介导的 mRNA 稳定相结合作为治疗老年人动脉生成的策略
- 批准号:
10597229 - 财政年份:2022
- 资助金额:
$ 6.79万 - 项目类别:
Combining Targeted Demethylation with Noncoding RNA-mediated mRNA Stabilization as a Strategy for Therapeutic Arteriogenesis in the Aged
将靶向去甲基化与非编码 RNA 介导的 mRNA 稳定相结合作为治疗老年人动脉生成的策略
- 批准号:
10631563 - 财政年份:2022
- 资助金额:
$ 6.79万 - 项目类别:
Reprogramming Macrophages to Improve Vascular Healing in Diabetes
重编程巨噬细胞以改善糖尿病血管愈合
- 批准号:
10260749 - 财政年份:2021
- 资助金额:
$ 6.79万 - 项目类别:
Reprogramming Macrophages to Improve Vascular Healing in Diabetes
重编程巨噬细胞以改善糖尿病血管愈合
- 批准号:
10426222 - 财政年份:2021
- 资助金额:
$ 6.79万 - 项目类别:
Reprogramming Macrophages to Improve Vascular Healing in Diabetes
重编程巨噬细胞以改善糖尿病血管愈合
- 批准号:
10674353 - 财政年份:2021
- 资助金额:
$ 6.79万 - 项目类别:
Reprogramming Macrophages to Improve Vascular Healing in Diabetes
重编程巨噬细胞以改善糖尿病血管愈合
- 批准号:
10709502 - 财政年份:2021
- 资助金额:
$ 6.79万 - 项目类别:
Development of Rac-Targeted Therapeutic Strategy for Treatment of Calcific Atherosclerosis
钙化动脉粥样硬化 Rac 靶向治疗策略的开发
- 批准号:
10064634 - 财政年份:2018
- 资助金额:
$ 6.79万 - 项目类别:
Development of Rac-Targeted Therapeutic Strategy for Treatment of Calcific Atherosclerosis
钙化动脉粥样硬化 Rac 靶向治疗策略的开发
- 批准号:
10304197 - 财政年份:2018
- 资助金额:
$ 6.79万 - 项目类别:
Development of Rac-Targeted Therapeutic Strategy for Treatment of Calcific Atherosclerosis
钙化动脉粥样硬化 Rac 靶向治疗策略的开发
- 批准号:
10531676 - 财政年份:2018
- 资助金额:
$ 6.79万 - 项目类别:
Calcific Atherosclerosis is Mediated by Macrophage Adhesion Signaling
钙化动脉粥样硬化是由巨噬细胞粘附信号介导的
- 批准号:
8733374 - 财政年份:2014
- 资助金额:
$ 6.79万 - 项目类别:
相似海外基金
Impact of alternative polyadenylation of 3'-untranslated regions in the PI3K/AKT cascade on microRNA
PI3K/AKT 级联中 3-非翻译区的替代多聚腺苷酸化对 microRNA 的影响
- 批准号:
573541-2022 - 财政年份:2022
- 资助金额:
$ 6.79万 - 项目类别:
University Undergraduate Student Research Awards
How do untranslated regions of cannabinoid receptor type 1 mRNA determine receptor subcellular localisation and function?
1 型大麻素受体 mRNA 的非翻译区如何决定受体亚细胞定位和功能?
- 批准号:
2744317 - 财政年份:2022
- 资助金额:
$ 6.79万 - 项目类别:
Studentship
MICA:Synthetic untranslated regions for direct delivery of therapeutic mRNAs
MICA:用于直接递送治疗性 mRNA 的合成非翻译区
- 批准号:
MR/V010948/1 - 财政年份:2021
- 资助金额:
$ 6.79万 - 项目类别:
Research Grant
Translational Control by 5'-untranslated regions
5-非翻译区域的翻译控制
- 批准号:
10019570 - 财政年份:2019
- 资助金额:
$ 6.79万 - 项目类别:
Translational Control by 5'-untranslated regions
5-非翻译区域的翻译控制
- 批准号:
10223370 - 财政年份:2019
- 资助金额:
$ 6.79万 - 项目类别:
Translational Control by 5'-untranslated regions
5-非翻译区域的翻译控制
- 批准号:
10455108 - 财政年份:2019
- 资助金额:
$ 6.79万 - 项目类别:
Synergistic microRNA-binding sites, and 3' untranslated regions: a dialogue of silence
协同的 microRNA 结合位点和 3 非翻译区:沉默的对话
- 批准号:
255762 - 财政年份:2012
- 资助金额:
$ 6.79万 - 项目类别:
Operating Grants
Analysis of long untranslated regions in Nipah virus genome
尼帕病毒基因组长非翻译区分析
- 批准号:
20790351 - 财政年份:2008
- 资助金额:
$ 6.79万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Search for mRNA elements involved in the compatibility between 5' untranslated regions and coding regions in chloroplast translation
寻找参与叶绿体翻译中 5 非翻译区和编码区之间兼容性的 mRNA 元件
- 批准号:
19370021 - 财政年份:2007
- 资助金额:
$ 6.79万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Post-transcriptional Regulation of PPAR-g Expression by 5'-Untranslated Regions
5-非翻译区对 PPAR-g 表达的转录后调控
- 批准号:
7131841 - 财政年份:2006
- 资助金额:
$ 6.79万 - 项目类别:














{{item.name}}会员




